Treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly improves progression-free survival (PFS) compared with chemotherapy plus pembrolizumab among patients with PD-L1-negative advanced nonsquamous non-small cell lung cancer (NSCLC), according to the OptiTROP-Lung06 study presented at ESMO 2026.
At a median follow-up of 9.7 months, patients treated with sac-TMT plus pembrolizumab demonstrated a significantly longer median PFS per blinded independent central review (BICR) compared with those who received chemotherapy plus pembrolizumab (15 vs 5.7 months; hazard ratio [HR], 0.49; p<0.0001). These findings translate to a 51-percent reduction in the risk of disease progression or death. [ESMO 2026, abstract LBA66]
Additionally, the 12-month PFS rate was higher in the sac-TMT group than in the chemotherapy group (51.1 percent vs 22.8 percent).
Consistent with the BICR findings, investigator-assessed median PFS also favoured the sac-TMT plus pembrolizumab compared with chemotherapy plus pembrolizumab (HR, 0.52).
Furthermore, the PFS benefit with sac-TMT plus pembrolizumab was generally consistent across prespecified subgroups.
Although overall survival (OS) data was immature at the time of analysis, a trend toward improved OS was observed with sac-TMT plus pembrolizumab compared with chemotherapy plus pembrolizumab (HR, 0.58), with a higher 12-month OS rate (77.6 percent vs 66.4 percent).
Among patients who discontinued treatment, more than half of the participants in each group received subsequent systemic anticancer therapy (57 percent in the sac-TMT group vs 54.1 percent in the chemotherapy group). Platinum-based chemotherapy was the most common subsequent systemic therapy, administered to 50.5 percent of patients in the sac-TMT group and 14.8 percent of patients in the chemotherapy group.
As assessed by BICR, the objective response rate was comparable between the sac-TMT and chemotherapy groups (50.2 percent vs 47.3 percent).
Notably, the sac-TMT regimen was associated with a higher rate of deep responses (28.8 percent vs 17.3 percent) and nearly doubled the median duration of response (DoR; 13.6 vs 6.8 months; HR, 0.47) compared with chemotherapy plus pembrolizumab.
Safety
Compared with those on chemotherapy plus pembrolizumab, patients who received sac-TMT plus pembrolizumab had fewer grade ≥3 treatment-emergent adverse events (TEAEs; 47.6 percent vs 60.6 percent), TEAEs leading to treatment discontinuation (5.7 percent vs 14.2 percent), and deaths (2.2 percent vs 6.2 percent).
“The safety profile was manageable and consistent with the known profiles of the individual agents, and no new safety signals were identified,” said Prof Caicun Zhou from Shanghai East Hospital, Tongji University, Shanghai, China.
New standard of care
This phase III, multicentre, open-label trial analysed 455 patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC who were randomized in a 1:1 ratio to receive sac-TMT 4 mg/kg Q2W (n=229) or pemetrexed 500 mg mg/m2 plus carboplatin AUC 5 or cisplatin 75 mg/m2 Q3W (n=226) in addition to pembrolizumab 400 mg Q6W.
“Sac-TMT plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in PFS … and showed a higher deep response rate and longer DoR, reflecting deeper and more durable responses, compared with chemotherapy plus pembrolizumab,” according to Zhou.
“Overall, the results from the OptiTROP-Lung06 study support sac-TMT plus pembrolizumab as a new standard of care for patients with PD-L1-negative advanced nonsquamous NSCLC without EGFR or ALK alterations,” he added.